α1-Antitrypsin dosing change results in savings

  • Published on
    12-Dec-2016

  • View
    212

  • Download
    0

Embed Size (px)

Transcript

<ul><li><p>Inpharma 1395 - 12 Jul 2003</p><p> Tailored pharmacokinetic dosing of IV1-antitrypsin augmentation therapy "markedlyreduces" the annual drug cost among patients with1-antitrypsin deficiency in Sweden, report researchersfrom that country. They used a computer simulation tochange the dosage regimens among five such patientswith emphysema who were receiving IV augmentationwith human 1-antitrypsin [Prolastin]; the dosagechanged from 120 mg/kg every two weeks to 12gtwice weekly. The new dosage decreased the annualmedian 1-antitrypsin consumption from 286g to 156gper patient and allowed the treatment to take place athome. Among four patients who went ahead with thenew home-based therapy, the annual total drug costfell by SEK780 000,* a saving of 30%.* Swedish kronor</p><p>Piitulainen E, et al. Tailored pharmacokinetic dosing allows self-administrationand reduces the cost of IV augmentation therapy with human alpha-(1)-antitrypsin. European Journal of Clinical Pharmacology 59: 151-156, Jun2003 800947189</p><p>1</p><p>Inpharma 12 Jul 2003 No. 13951173-8324/10/1395-0001/$14.95 Adis 2010 Springer International Publishing AG. All rights reserved</p></li></ul>

Recommended

View more >